(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.43%.
Cormedix's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CRMD's revenue for 2024 to be $802,724,089, with the lowest CRMD revenue forecast at $802,724,089, and the highest CRMD revenue forecast at $802,724,089.
In 2025, CRMD is forecast to generate $3,680,984,779 in revenue, with the lowest revenue forecast at $3,680,984,779 and the highest revenue forecast at $3,680,984,779.